Clinical-Pathologic Predictors of Tumor Response, Survival, and Toxicity in Patients with Rectal Adenocarcinoma Undergoing Trimodality Therapy

Study ID
STU 112011-080

Cancer Related
Yes

Healthy Volunteers
No

Study Sites

  • Parkland Health & Hospital System
  • UT Southwestern Ambulatory Services
  • UT Southwestern University Hospital– Zale Lipshy
  • UT Southwestern University Hospital—St. Paul

Contact
Silvia Pilarski
214-633-1752
silvia.pilarski@utsouthwestern.edu

Principal Investigator
Jeffrey Meyer

Summary

This study would be a retrospective review of the currently existing records for patients with rectal adenocarcinoma treated between 1/1/1995to the11.30.2011. We will evaluate the relationship between clinical-pathologic features of the patient’s primary tumor as well as host factors to determine if there are novel predictors of tumor response and patient survival.

Participant Eligibility

: UT-Southwestern and Parkland patients who have undergone combined-modality therapy for rectal adenocarcinoma from 1/1/1995 to 11.30.2011.